Polatuzumab Vedotin

Common brands: Polivy, Rituxan, Cyclophosphamide, Frindovyx, Doxorubicin Hydrochloride

Top reporter: Genentech, Inc.

CD20-directed Cytolytic Antibody [EPC]Corticosteroid [EPC]Alkylating Drug [EPC]Platinum-based Drug [EPC]Nucleoside Metabolic Inhibitor [EPC]
9,110
Total Reports
6,703
Serious Reports
1,977
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.70%)

Patient Demographics

Male
4,243
Female
2,993

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Polatuzumab Vedotin.

# Reaction Reports % of Total
1 DISEASE PROGRESSION 1,972
14.8%
2 OFF LABEL USE 1,267
9.5%
3 DEATH 751
5.6%
4 NEUTROPENIA 557
4.2%
5 ANAEMIA 527
4.0%
6 COVID-19 521
3.9%
7 FEBRILE NEUTROPENIA 486
3.6%
8 DRUG INEFFECTIVE 476
3.6%
9 PYREXIA 474
3.6%
10 BLOOD LACTATE DEHYDROGENASE INCREASED 416
3.1%
11 PLATELET COUNT DECREASED 414
3.1%
12 NEUTROPHIL COUNT DECREASED 391
2.9%
13 CYTOKINE RELEASE SYNDROME 389
2.9%
14 THROMBOCYTOPENIA 379
2.8%
15 WHITE BLOOD CELL COUNT DECREASED 375
2.8%
16 PNEUMONIA 367
2.8%
17 DIFFUSE LARGE B-CELL LYMPHOMA 363
2.7%
18 LYMPHOMA 361
2.7%
19 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 327
2.5%
20 DIARRHOEA 306
2.3%
21 NEUROPATHY PERIPHERAL 290
2.2%
22 MALIGNANT NEOPLASM PROGRESSION 287
2.2%
23 MYELOSUPPRESSION 254
1.9%
24 INFECTION 251
1.9%
25 SEPSIS 232
1.7%
26 LYMPHOCYTE COUNT DECREASED 213
1.6%
27 NAUSEA 176
1.3%
28 CYTOPENIA 175
1.3%
29 ASPARTATE AMINOTRANSFERASE INCREASED 165
1.2%
30 PANCYTOPENIA 162
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.